Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Tefferi

Showing results (241-250 of 346) with videos related to

Pageof 35
Sort By:
Blood Cancer Journal|January 16, 2016
Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemiaM M Patnaik, T L Lasho, P Vijayvargiya, et al.
Leukemia|November 9, 2011
SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patientsT L Lasho, C M Finke, C A Hanson, et al.
Leukemia|October 15, 2010
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patientsD Caramazza, K H Begna, N Gangat, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 12, 2002
Variations in bone density among persons of African heritageL J Melton III, M A Marquez, S J Achenbach, et al.
Leukemia|February 27, 2014
Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impactA Tefferi, T L Lasho, C Finke, et al.
Blood Cancer Journal|March 12, 2016
Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosisA Tefferi, A Al-Kali, K H Begna, et al.
American Journal of Clinical Oncology|October 16, 1999
Phase II study of 2-chlorodeoxyadenosine in combination with chlorambucil in previously untreated B-cell chronic lymphocytic leukemiaA Tefferi, R Levitt, C Y Li, et al.
Leukemia|September 14, 2011
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617FA Tefferi, T Jimma, N H Sulai, et al.
Blood Cancer Journal|August 8, 2015
A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosisA Pardanani, A Tefferi, C Jamieson, et al.
Leukemia|October 8, 2013
U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotypeA Tefferi, C M Finke, T L Lasho, et al.
Pageof 35

Showing results (241-250 of 346) with videos related to

Sort By:
Pageof 35
Blood Cancer Journal|January 16, 2016
Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemiaM M Patnaik, T L Lasho, P Vijayvargiya, et al.
Leukemia|November 9, 2011
SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patientsT L Lasho, C M Finke, C A Hanson, et al.
Leukemia|October 15, 2010
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patientsD Caramazza, K H Begna, N Gangat, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|July 12, 2002
Variations in bone density among persons of African heritageL J Melton III, M A Marquez, S J Achenbach, et al.
Leukemia|February 27, 2014
Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impactA Tefferi, T L Lasho, C Finke, et al.
Blood Cancer Journal|March 12, 2016
Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosisA Tefferi, A Al-Kali, K H Begna, et al.
American Journal of Clinical Oncology|October 16, 1999
Phase II study of 2-chlorodeoxyadenosine in combination with chlorambucil in previously untreated B-cell chronic lymphocytic leukemiaA Tefferi, R Levitt, C Y Li, et al.
Leukemia|September 14, 2011
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617FA Tefferi, T Jimma, N H Sulai, et al.
Blood Cancer Journal|August 8, 2015
A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosisA Pardanani, A Tefferi, C Jamieson, et al.
Leukemia|October 8, 2013
U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotypeA Tefferi, C M Finke, T L Lasho, et al.
Pageof 35